Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation inFollicular Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 12, 2013, Pages 1695-1701

  Derenzini, Enrico ^a   Stefoni, Vittorio ^a   Maglie, Roberto ^a   Casadei, Beatrice ^a   Pellegrini, Cinzia ^a   Broccoli, Alessandro ^a   Stefani, Giulia ^a   Fanti, Stefano ^b   Motta, Maria Rosa ^a   Narducci, Riccardo ^a   Argnani, Lisa ^a   Zinzani, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autologous stem cell transplantation; Follicular lymphoma; Hematopoietic stem cell mobilization; Plerixafor; Radioimmunotherapy; Yttrium 90 ibritumomab tiuxetan

Indexed keywords

BLEOMYCIN; CARMUSTINE; CD34 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PLERIXAFOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; COMPASSIONATE USE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG MEGADOSE; ENGRAFTMENT; EVENING DOSAGE; FEASIBILITY STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GRAFT SALVAGE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD STEM CELL; RADIOIMMUNOTHERAPY; STEM CELL MOBILIZATION; THERAPY EFFECT; TREATMENT OUTCOME;

AUTOLOGOUS STEM CELL TRANSPLANTATION; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL MOBILIZATION; PLERIXAFOR; RADIOIMMUNOTHERAPY; YTTRIUM-90 IBRITUMOMAB TIUXETAN;

ADULT; AGED; ALGORITHMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84887535499     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.09.004     Document Type: Article

References (39)

1. Anderson J.R., Armitage J.O., Weisenburger D.D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998, 9:717-720.
2. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
3. Gribben J.G. How I treat indolent lymphoma. Blood 2007, 109:4617-4626.
4. Fisher R.I., LeBlanc M., Press O.W., et al. New treatment options have changed the survival of patients with follicular lymphoma. JClin Oncol 2005, 23:8447-8452.
5. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
6. McLaughlin P. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?. Clin Lymph Myel Leuk 2011, 11(Suppl 1):S91-S95.
7. Sehn L.H., Fenske T.S., Laport G.G. Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18(1 Suppl):S82-S91.
8. Herold M., Haas A., Srock S., et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. JClin Oncol 2007, 25:1986-1992.
9. Marcus R., Imrie K., Solal-Celigny P., et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. JClin Oncol 2008, 26:4579-4586.
10. Salles G., Seymour J.F., Offner F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42-51.
11. Federico M., Dondi A., Sacchi S., et al. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). JClin Oncol 2012, 30(Suppl). abstr 8006.
12. Gill S., Carney D., Ritchie D., et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010, 21:331-334.
13. Waterman J., Rybicki L., Bolwell B., et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 2012, 47:488-493.
14. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. JClin Oncol 2001, 19:3918-3928.
15. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. JClin Oncol 2002, 20:2453-2463.
16. Kaminski M.S., Tuck M., Estes J., et al. 131I-tositumomab therapy as initialtreatment for follicular lymphoma. NEngl J Med 2005, 352:441-449.
17. Scholz C.W., Pinto A., Linkesch W., et al. 90Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an International Multicenter Phase II Clinical Trial. JClin Oncol 2013, 31:308-313.
18. Morschhauser F., Radford J., Van Hoof A., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. JClin Oncol 2008, 26:5156-5164.
19. Press O.W., Unger J.M., Braziel R.M., et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. JClin Oncol 2006, 24:4143-4149.
20. Link B.K., Martin P., Kaminski M.S., et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. JClin Oncol 2010, 28:3035-3041.
21. Zinzani P.L., Tani M., Pulsoni A., et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008, 9:352-358.
22. Zinzani P.L., Tani M., Pulsoni A., et al. Aphase II trial of short course fludarabine, mitoxantrone, rituximab followed by (9)(0)Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol 2012, 23:415-420.
23. Bierman P.J., Vose J.M., Anderson J.R., et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. JClin Oncol 1997, 15:445-450.
24. Cao T.M., Horning S., Negrin R.S., et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001, 7:294-301.
25. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. JClin Oncol 2003, 21:3918-3927.
26. Ladetto M., De Marco F., Benedetti F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008, 111:4004-4013.
27. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:2667-2674.
28. Al Khabori M., de Almeida J.R., Guyatt G.H., et al. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. JNatl Cancer Inst 2012, 104:18-28.
29. Hohloch K., Zinzani P.L., Linkesch W., et al. Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. Bone Marrow Transplant 2011, 46:901-903.
30. Cooney J., Stiff P., Kaminski M. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab). Bone Marrow Transplant 2002, 29:523-525.
31. Derenzini E., Stefoni V., Pellegrini C., et al. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymph 2009, 50:1824-1829.
32. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
33. Zinzani P.L., Tani M., Molinari A.L., et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002, 87:816-821.
34. Zinzani P.L., Tani M., Gabriele A., et al. High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymph 2004, 45:321-326.
35. Stiff P.J., Micallef I., Nademanee A.P., et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011, 17:1146-1153.
36. Olivieri A., Offidani M., Montanari M., et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998, 83:329-337.
37. Kiss J.E., Rybka W.B., Winkelstein A., et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997, 19:303-310.
38. Kaplan E.L., Meier P. Nonparametric estimations from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
39. Zinzani P.L., Rossi G., Franceschetti S., et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 2010, 16:3998-4004.